Bayer bought the manufacturer of medicines for women’s health

German pharmaceutical manufacturer Bayer will pay about $ 900 million for the British biotechnology company specializing in the production of goods for women’s health. Pre-payment for KaNDy Therapeutics will amount to 425 million dollars, writes MedCity News.

The deal is aimed at further strengthening of the position of Bayer in the market for women’s health. It is expected that the deal will close next month after receiving approval of competition authorities.

In addition to the initial payment, Bayer agreed to pay milestone payments for the successful development of an experimental drug NT-814 is designed for the correction of vasomotor symptoms of menopause. NT-814 is a non-hormonal receptor antagonist neirokinina to 1.3, which should be taken once a day orally. Currently undergoing clinical studies phase III, their completion is scheduled for 2021. According to analysts, sales of the NT-814 can reach 1 billion euros (1.18 billion dollars).

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]